Navigation Links
Delcath to Present at Upcoming Investor Conferences
Date:3/2/2011

NEW YORK, March 2, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that executive management will present an overview of the Company's business strategy and recent corporate developments at the following investor conferences:

  • The Cowen and Company Healthcare Conference in Boston.  Mr. Eamonn Hobbs, Chief Executive Officer, and Mr. David McDonald, Chief Financial Officer, are scheduled to present an overview of the Company on Tuesday, March 8, 2011 at 10:15 a.m. ET.
  • ROTH Capital Annual OC Growth Stock Conference in Laguna Niguel, California.  Mr. Hobbs is scheduled to present an overview of the Company on Monday, March 14, 2011 at 1:30 p.m. PT.

  • Attendance at each of these conferences is by invitation only. Delcath will offer live and audio webcasts of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentations will be available for 90 days, also at www.delcath.com.

    About Delcath SystemsDelcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

    Media Contact:Gregory Gin/Doug Sherk

    Janine McCargoEVC Group

    EVC Group646-445-4801/415-896-6818

    646-688-0425
    '/>"/>

    SOURCE Delcath Systems, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Delcath Systems Receives Refusal to File Letter From FDA
    2. Delcath Achieves ISO 13485 Certification
    3. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
    4. Delcath Systems Announces Third Quarter Progress Report Conference Call
    5. Delcath Strengthens Research and Development Team with Key Appointments
    6. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
    7. Delcath to Present at the William Blair Emerging Growth Stock Conference
    8. Delcath to Present at the JMP Securities Healthcare Conference
    9. Delcath Systems Announces Completion of Common Stock Offering
    10. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
    11. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/3/2017)... Calif. , May 3, 2017 ... of any hospital or healthcare facility. Commonly referred ... room is equipped with diagnostic imaging technology to ... of the heart. In these spaces, a team ... catheterization, balloon angioplasty, percutaneous coronary intervention, congenital heart ...
    (Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
    (Date:5/2/2017)... and NEW YORK ... As the leading distributor of market intelligence, ... European Med Tech Reimbursement Consulting AB that ... Tech Reimbursement Consulting AB,s proprietary market analyses through the ... professionals around the world easy access to complete product ...
    Breaking Medicine Technology:
    (Date:5/28/2017)... ... 28, 2017 , ... HYPERAMS, LLC announced it will perform the ... in Lima, Ohio. The sale began this week and the inventory is expected to ... scrubs, uniforms, and medical accessories, including blood pressure cuffs, stethoscopes, CPR masks, as well ...
    (Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
    (Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar with ... new study from the Osteoarthritis Initiative shows that certain people who experience ... this in advance may give doctors the opportunity to treat patients before the problem ...
    (Date:5/26/2017)... ... May 26, 2017 , ... The ... seminar to focus on current legislative activity and the latest regulatory concerns impacting ... p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at the ...
    (Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are ... menus. , “Boar’s Head fresh sliced meats and cheeses featured in these ...
    Breaking Medicine News(10 mins):